News Headlines
-
Theragent And Pluristyx Enter Partnership To Streamline And Advance iPSC-derived Therapy Development
5/7/2024
Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell- and tissue-based therapies, has announced a partnership with Pluristyx, Inc., an early stage, privately held biotechnology company specializing in induced Pluripotent Stem Cell (iPSC) products.
-
CytomX Therapeutics Announces Clinical Collaboration With Merck To Evaluate CX-801 In Combination With KEYTRUDA® (pembrolizumab)
5/7/2024
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the US and Canada) for CytomX’s first-in-human Phase 1 clinical trial assessing the clinical activity of CX-801, a dually-masked interferon-alpha2b cytokine in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab).
-
Selvita Completes Acquisition Of PozLab And Significantly Expands Its Drug Development Capabilities
5/7/2024
Selvita S.A. [WSE: SLV] announced today completion of a strategic transaction in which it has acquired 100% of shares in PozLab. The closing of the transaction comes shortly after the announcement of the transaction on March 27, 2024.
-
Sharp Services Announces Expansion In Pennsylvania To Facilitate Growth In Sterile Injectable Market
5/6/2024
Sharp, a global leader in contract packaging, clinical supply services and small-scale sterile manufacturing, has today announced plans for the expansion of its Macungie, PA site in North America to increase its production capacity for sterile injectables secondary packaging.
-
LSL Pharma Group Enters Into Binding Agreement To Acquire Quebec Competitor
5/6/2024
LSL PHARMA GROUP INC. (TSXV: LSL) ("the Company" or "LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to announce that it has entered into a binding Letter of Intent ("LOI") to acquire profitable privately held, Quebec-based competing contract drug manufacturer ("CDMO") specialized in the formulation, production, and marketing of natural products ("Target Co") . Target Co. and its shareholders are at arm’s length from LSL Pharma.
-
Grand River Aseptic Manufacturing Expands Syringe And Cartridge Capacity With New 150,000 sq. ft. Syringe And Cartridge Filling Center
5/6/2024
Grand River Aseptic Manufacturing (“GRAM”), a leading sterile injectable contract manufacturer of biologics, small molecules, and vaccines, announces its third world-class facility in five years.
-
Wacker Expands Production Capacity For Biopharmaceuticals In San Diego
5/6/2024
As part of its growth strategy for the BIOSOLUTIONS life-science division, WACKER is increasing capacities in the field of biopharmaceuticals for advanced therapies.
-
Akoya Biosciences Opens Operations And Manufacturing Center Of Excellence In Marlborough, Massachusetts
5/6/2024
Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company’s PhenoCycler®-Fusion and the PhenoImager® HT platforms.
-
Kindeva Drug Delivery Invests In Second Manufacturing Line For Greener Inhalers At UK Manufacturing Site
5/6/2024
Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low-GWP (Global Warming Potential) propellants in its Loughborough, U.K., facility.
-
Alkermes plc Completes Sale Of Athlone, Ireland Facility To Novo Nordisk
5/2/2024
Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the transaction, Alkermes will receive a one-time cash payment for the facility and certain related assets of approximately $91 million.